Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant global health challenge, particularly in resource-limited settings. This article presents a comprehensive approach to the effective management of enteric fever, reinforcing the importance of early diagnosis, appropriate antibiotic therapy, and preventive measures.
Early diagnosis is crucial in managing enteric fever. Rapid diagnostic tests (RDTs) are gaining acceptance due to their ease of use and quick turnaround. However, their sensitivity and specificity vary. Blood culture remains the gold standard for diagnosis, although it may not always be feasible in resource-limited settings.
Antibiotic resistance is a growing concern in the treatment of enteric fever. Empirical therapy should ideally be guided by local antimicrobial susceptibility patterns. Fluoroquinolones, third-generation cephalosporins, and azithromycin are commonly used. Duration of therapy typically ranges from 7 to 14 days, depending on the patient's clinical response.
Prevention of enteric fever largely depends on improving sanitation and access to clean water. Vaccination also plays a crucial role. Both Vi polysaccharide and Ty21a vaccines are recommended for high-risk populations and travelers to endemic areas. However, their protective efficacy is not 100%, underscoring the need for complementary preventive measures.
Managing enteric fever effectively requires a multi-faceted approach. Early diagnosis, appropriate antibiotic therapy, and preventive measures are all integral components. As healthcare professionals, it is our responsibility to stay updated with the latest diagnostic tools, understand local antibiotic resistance patterns, and advocate for improved sanitation and vaccination programs. This comprehensive strategy will help us reduce the burden of this preventable disease.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation